DGAP-News

DR. MARIOLA SÖHNGEN WILL LEAVE MANAGEMENT BOARD OF PAION AG AS OF 31 OCTOBER 2015 AND PAION PLANS NEW COMPOSITION OF EXECUTIVE MANAGEMENT - Seite 3

appointment of a COO for Europe with expertise in supply chain and sales is
to strengthen the team as soon as possible. It is time to line-up the
executive management of PAION for the future challenges."

###

About Remimazolam
Remimazolam is an innovative ultra-short-acting general
sedative/anesthetic. As a result of its short duration of action and good
controllability, it has a preferable efficacy and safety profile relative
to other currently marketed anesthesia compounds. Remimazolam's rapid
offset is a consequence of its metabolism by tissue esterase enzymes that
are widely distributed throughout the body. Remimazolam has potential in
three indications:

- Procedural sedation (Lead indication US)

- General anesthesia (Lead indication EU, Japan)

- ICU sedation (Phase II Japan)

Remimazolam is available for licensing outside China, Russia (CIS) Turkey,
MENA Region, South Korea and Canada, where the compound is partnered with
Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm.

About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The
company has a track record of developing hospital-based treatments for
which there is substantial unmet medical need. PAION's strategy is to
participate in the commercialization of Remimazolam and extend its business
with a focus on anesthesia/critical care products. Remimazolam is the
building block for its future marketing activities.

For more information please visit www.paion.com

PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: [phone]
E-mail: [e-mail]
www.paion.com

Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.



---------------------------------------------------------------------

07.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
376095 07.07.2015